Our study supports the hypothesis that such receptors may contribute to migraine and highlights the importance of developing specific antibodies or antagonists targeting CTR-based receptors, such as the AMY1-receptor, to probe the drug development potential of this receptor in the treatment or prevention of migraine. This evidence concerns the gene CALCR and migraine disorder.